Location: Home >> Identification of Prognostic Related Gene Expression Profile in Hepatocellular Carcinoma
Human Hepatocellular Carcinoma (HCC) is one of the most common and aggressive types of cancer. With over 70,000 deaths occurring worldwide from 2015 to 2022, it is the second major cause of cancer-related mortality. The high mortality associated with this disease is mainly attributed to the inability to diagnose HCC patients at an early stage. Gene expression (RNA-seq) data from 371 human HCC samples were downloaded from the TCGA data portal at the National Cancer Institute and analyzed to define the molecular characteristics of the tumors and their association with cancer survival. A total of 2481 genes that correlated to cancer survival and tumor stages were identified. GSEA analysis further identified that down-regulated lipid metabolism-related pathways and oxidative stress pathways may be involved in cancer progression. Some genes such as acyl-CoA dehydrogenase very long chain (LCAD), ApoA1, Aldo-keto reductase family 1 member D1 (AKR1D1), Retinol binding protein 5(RBP5), Dimethylaniline monooxygenase [N-oxide-forming] 5 (FMO5), and Oxidative stress-induced growth inhibitor 1(OKL38 family) may be potential biomarkers for HCC progression. In addition, we also observed potential virals involved in the expression data.
[1] Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015, 136, E359–E386, doi:10.1002/ijc.29210.
[2] Sangineto M, Villani R, Cavallone F, Romano A, Loizzi D, and ServiddioG.Lipid Metabolism in Development and Progression of Hepatocellular Carcinoma. Cancers 2020, 12:1419.
[3] Rawla, P.; Sunkara, T.; Muralidharan, P.; Raj, J.P. Update in global trends and etiology of hepatocellular carcinoma. Contemp. Oncol. 2018, 22, 141–150, doi:10.5114/wo.2018.78941.
[4] Gluer, A.M.; Cocco, N.; Laurence, J.M.; Johnston, E.S.; Hollands, M.J.; Pleass, H.C.; Richardson, A.J.; Lam, V.W. Systematic review of actual 10-year survival following resection for hepatocellular carcinoma. HPB Off. J. Int. HepatoPancreato Biliary Assoc. 2012, 14, 285–290, doi:10.1111/j.1477-2574.2012.00446.x.
[5] Wheeler D, and Roberts L. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell. 2017, 169(7): 1327–1341.
[6] Meng C, Shen X, and Jiang W.Potential biomarkers of HCC based on gene expression and DNA methylation profiles. Oncol Lett. 2018, 16: 3183–3192.
[7] Qin L, Huang D, Huang J, andHuang H. New biomarkers and therapeutic targets of human liver cancer: Transcriptomic findings. Biofactors. 2021; 47:1016-1031.
[8] Hu B, Yang X, Sang X. Construction of a lipid metabolism-related and immune-associated prognostic signature for hepatocellular carcinoma Cancer Med, 2020, 9: 7646-7662.
[9] Li W, Kun Liu K, Chen Y, Zhu M, and Li M, Role of Alpha-Fetoprotein in Hepatocellular Carcinoma Drug Resistance. Curr Med Chem. 2021, 28:1126-1142.doi: 10.2174/0929867327999200729151247.
[10] SkawranB,Steinemann D, Weigmann A, Flemming P, Becker T, Flik J, Kreipe H, Schlegelberger B and Wilkens L. Gene ex-pression profiling in hepatocellular carcinoma: upregulation of genes in amplified chromosome regions. Modern Pathology 2008, 21: 505–516.
[11] Jin Y, Lee W, Toh S, Tennakoon C, Toh H, Chow P, Chung A, Chong S, Ooi L, Sung W and Lee C. Comprehensive analysis of transcriptome profiles in hepatocellular carcinoma J Transl Med 17, 273 (2019).
[12] Hass H, Vogel U, Scheurlen M, and Jobst J. Gene-expression Analysis Identifies Specific Patterns of Dysregulated Molecular Pathways and Genetic Subgroups of Human Hepatocellular Carcinoma. Anticancer Res. 2016, 36: 5087-5096.
[13] Chung E, Sung Y, Farooq M, Kim Y, Im S, Tak W, Hwang Y, Kim Y, Han H, Kim J, and Kim M. Gene expression profile analysis in human hepatocellular carcinoma by cDNA microarray. Mol Cell. 2002, 14:382-387.
[14] Liu J, Sun G, Pan S, Qin M, Ouyang R, Li Z, and Huang J. The Cancer Genome Atlas (TCGA) based m6A methylation-related genes predict prognosis in hepatocellular carcinoma. Bioengineered. 2020; 11: 759–768.
[15] XuX, Chen W, Miao R, Zhou Y, Wang Z, Zhang L, Qu K, Pang Q, Wang R, and Liu C. Survival Analysis of Hepatocellular Carcinoma: A Comparison Between Young Patients and Aged Patients, Chin Med J (Engl). 2015, 128:1793–1800.
[16] Wright G, Simon R. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics, 2003, 19:2448-2455.
[17] Smyth G. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Molec. Biol., 2004, vol. 3 Article 3.
[18] Takada Y, Miyagi R, Takahashi A, Endo T, Osada N. A Generalized Linear Model for Decomposing Cis-regulatory, Parent-of-Origin, and Maternal Effects on Allele-Specific Gene Expression. Genes|Genomes|Genetics, 2017, 7: 2227–2234.
[19] Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M, Paulovich A, Pomeroy S, Golub T, Lander E, and Mesirov J. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. PNAS 2005, 102:15545-15550.
[20] Kanehisa M, and Sato Y. KEGG Mapper for inferring cellular functions from protein sequences. Protein Sci. 2020, 29:28-35.
[21] Ge S, Son E, and Yao R. iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data. BMC Bioinformatics 2018, 19:534.
[22] Wan Z, Zhang X, Luo Y, and Zhao B. Identification of Hepatocellular Carcinoma-Related Potential Genes and Pathways Through Bioinformatic-Based Analyses. Genetic Testing and Molecular Biomarkers. 2019. 23:766-777.
[23] Chen X, Cheung S, So S, Fan S, Barry C, Higgins J, Lai K, Ji J, Dudoit S, Ng I, Rijn M, Botstein D, and Brown P. Gene Ex-pression Patterns in Human Liver Cancers. Molecular Biology of the Cell, 2002 13:1803-2191.
[24] Carone C, Olivani A, Dalla Valle R, Manuguerra R, Silini E, Trenti T, Missale G, and Cariani E. Immune gene expression profile in hepatocellular carcinoma and surrounding tissue predicts time to tumor recurrence. Liver Cancer, 2018, 277–294.
[25] Liu Z, Zhang R, Yong Y, Zhang Z, Li C, Chen Z, and Bian H. Identification of crucial genes based on expression profiles of hepatocellular carcinomas by bioinformatics analysis. Peer J, 20197:e7436.
[26] Shangguan H, Tan S, and Zhang J. Bioinformatics analysis of gene expression profiles in hepatocellular carcinoma. Eur Rev Med, 2015, 19(11):2054-2061.
[27] Beaufrère A, Caruso S, Calderaro J, Poté N, Bijot JC, Couchy G, Cauchy F, Vilgrain V, Zucman-Rossi J, and Paradis V. Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. J Hepatol, 2022, 76:343-352.
[28] Hu B, JLin J, Yang X, and Sang X. Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune microenvi-ronment: A review. 2020 53:e12772. doi: 10.1111/cpr.12772.
[29] Nwosu Z, Battello N, Rothley M, Piorońska W, Sitek B, Ebert MP, Hofmann U, Sleeman J, Wölfl S, Meyer C, Megger D, and Dooley S. Liver cancer cell lines distinctly mimic the metabolic gene expression pattern of the corresponding human tumours. J Exp Clin Cancer Res., 2018 37:211.
[30] Hao Q, Li T, Zhang X, Gao P, Gao P, Li S1, and Geng Z. Expression and roles of fatty acid synthase in hepatocellular carcinoma. Onco. Rep., 2014; 32:2471-2476.
[31] Ni X, Yi Y, Fu Y, Cai X, Liu G, Huang J, Gan W, Xu J, Shuang-Jian, and Qiu S. Role of Lipids and Apolipoproteins in Pre-dicting the Prognosis of Hepatocellular Carcinoma After Resection. Onco Targets Ther., 2020, 13:12867-12880.
[32] Liu Y, Sogawa K, Sunaga M. Increased concentrations of apo A-I and apo A-II fragments in the serum of patients with hepa-tocellular carcinoma by magnetic beads-assisted MALDI-TOF mass spectrometry. Am J Clin Pathol., 2014; 141(1):52–61.
[33] Suzuki, H Kohjima M, Tanaka M, Goya T, ItohS,Yoshizumi T, Mori M, Tsuda M, Takahashi M, Kurokawa M, Imoto K, Tashiro S, Kuwano A, Kato M, Okada S, Nakamura M, and Ogawa Y. Metabolic Alteration in Hepatocellular Carcinoma: Mechanism of Lipid Accumulation in Well-Differentiated Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2021. https://doi.org/10.1155/2021/8813410.
[34] Nakagawa H, Hayata Y, and Koike K. Lipid Metabolic Reprogramming in Hepatocellular Carcinoma. Cancers (Basel). 2018;10: 447-460. doi:10.3390/cancers10110447.
[35] Xu W, Chen L, Chen X, Liu Y, Zheng T, Song J, Xu W, Li P, Zhang M, Xiao C, Guleng B, and Ren J. Silencing ECHS1 atte-nuates the proliferation and induces the autophagy of hepatocellular carcinoma via impairing cell metabolism and activating AMPK. Neoplasma. 2015, 62:872-80. doi: 10.4149/neo_2015_106.
[36] Zhu, P., Feng, R., Lu, X., Liao, Y., Du, Z., Zhai, W., and Chen, K. (2021). Diagnostic and prognostic values of AKR1C3 and AKR1D1 in hepatocellular carcinoma. Aging, 13(3), 4138–4156. https://doi.org/10.18632/aging.202380.
[37] Penning T, Wangtrakuldee P, and Auchus R. Structural and Functional Biology of Aldo-Keto Reductase Steroid-Transformation Enzymes, Endocrine Reviews, 2019,40: 447–475, https://doi.org/10.1210/er.2018-00089.
[38] Yuan X, Wang B, Yang L, and Zhang Y. The role of ROS-induced autophagy in hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2018 42(4):306-312. doi: 10.1016/j.clinre.2018.01.005.
[39] Liu M, Li Y, Chen L, Chan T, Song Y, Fu L, Zeng T, Dai YD, Zhu YH, Li Y, Chen J, Yuan Y, and Guan X. Allele-specific imbalance of oxidative stress-induced growth inhibitor 1 associates with progression of hepatocellular carcinoma. Gastroenter-ology. 2014 146(4):1084-96. doi: 10.1053/j.gastro.2013.12.041.
[40] Charrière B, Maulat C, Suc B, and Muscari F. Contribution of alpha-fetoprotein in liver transplantation for hepatocellular car-cinoma. World J Hepatol 2016; 8: 881-890. 10.4254/wjh.v8.i21.881.
[41] Muscari F, Guinard JP, Kamar N, Peron JM, Otal P, and Suc B. Impact of preoperative α-fetoprotein level on disease-free sur-vival after liver transplantation for hepatocellular carcinoma. World J Surg., 2012, 36(8):1824-31. doi: 10.1007/s00268-012-1587-z.
[42] Blank S, Wang Q, Fiel M, Luan W, Kim K, Kadri H, Mandeli J, and Hiotis S. Assessing prognostic significance of preoperative alpha-fetoprotein in hepatitis B-associated hepatocellular carcinoma: normal is not the new normal. Ann Surg Oncol., 2014 Mar; 21(3):986-94. doi: 10.1245/s10434-013-3357-z.
[43] El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012, 142(6):1264-1273.e1. doi: 10.1053/j.gastro.2011.12.061.
[44] Zamor, P. J., deLemos, A. S., & Russo, M. W. (2017). Viral hepatitis and hepatocellular carcinoma: etiology and management. Journal of gastrointestinal oncology, 8(2), 229–242. https://doi.org/10.21037/jgo.2017.03.14.
[45] Zhang X, Guan L, Tian H, Zeng Z, Chen J, Huang D, Sun J, Guo J, Cui H, Li Y. Risk Factors and Prevention of Viral Hepati-tis-Related Hepatocellular Carcinoma. Front Oncol. 2021, Sep 9; 11:686962. doi: 10.3389/fonc.2021.686962.
[46] Yang J, Hainaut P, Gores G, Amadou A, Plymouth A, and Roberts L. A Global View of Hepatocellular Carcinoma: Trends, Risk, Prevention and Management. Nat Rev Gastroenterol Hepatol, (2019) 16(10):589–604. 10.1038/s41575-019-0186-y.
Justin Fan, He Wang. Identification of Prognostic Related Gene Expression Profile in Hepatocellular Carcinoma. International Journal of Medicine Frontiers, 2023, 6(1), 11-24.
Copyright © 2022 Damray Co., Ltd. Privacy Policy | Terms and Conditions
